LOS ANGELES - With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.
The study, published online in the Journal of Nephrology, noted that the two classes of medications, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB), have slightly different mechanisms and could theoretically have differing outcomes.
The researchers also noted that previous studies had suggested that "ACEI may lead to a kinin-mediated increase in insulin sensitivity not seen with ARB. This could potentially lower the cardiovascular risk in patients on peritoneal dialysis because they are exposed to high glucose loads [in their dialysate] that may lead to insulin resistance and its associated cardiovascular risk."
"Despite this suggestion, we could find no previous study that had compared these two classes of medications head-to-head in patients on peritoneal dialysis to see if ACEI might indeed be better than ARB in this patient population," said Jenny Shen, MD, an LA BioMed lead researcher and corresponding author of the study. "Our study found no significant difference in the effectiveness of the two classes of medications. Although randomized clinical trials would be needed to confirm these observational results, our study suggests that physicians can use ACEI and ARB interchangeably to prevent cardiovascular risks in their peritoneal dialysis patients."
Using a national database, the U.S. Renal Data System, the researchers surveyed records for all Medicare Part D (a federal prescription drug program) patients who underwent peritoneal dialysis from 2007 to 2011. Of those, they found 1,892 patients using either drug class. Surveying their medical records, the researchers said they found no difference in cardiovascular events or deaths between the users for each medication.
Other researchers were: Lynn Leng, LA BioMed; Anjali B. Saxena, Maria E. Montez-Rath and Tara I. Chang from Stanford University School of Medicine, and Wolfgang C. Winkelmayer also from Stanford and Baylor College of Medicine. Funding support came from Grants F32DK096765, K23DK103972 and K23DK095914 from the National Institute of Diabetes, Digestive, and Kidney Diseases. The Stanford Nephrology fellowship program was supported by Grant T32DK007357. Dr. Shen was also supported by the Satellite Dialysis Clinical Investigator Award from the National Kidney Foundation, Grant KL2TR000122 from the NIH/National Center for Advancing Translational Science and a generous gift honoring the life and work of nephrologist Henry Shavelle, MD.
To view the article, please visit: http://link.
About LA BioMed
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved diagnostics and treatments for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit http://www.